AR087727A1 - Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos - Google Patents
Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usosInfo
- Publication number
- AR087727A1 AR087727A1 ARP120101345A ARP120101345A AR087727A1 AR 087727 A1 AR087727 A1 AR 087727A1 AR P120101345 A ARP120101345 A AR P120101345A AR P120101345 A ARP120101345 A AR P120101345A AR 087727 A1 AR087727 A1 AR 087727A1
- Authority
- AR
- Argentina
- Prior art keywords
- ala
- absent
- leu
- arg
- ser
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 239000000122 growth hormone Substances 0.000 title abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 6
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 5
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 5
- 101710142969 Somatoliberin Proteins 0.000 abstract 5
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 abstract 4
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 abstract 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 4
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 abstract 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 2
- 229960003104 ornithine Drugs 0.000 abstract 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- SXGMVGOVILIERA-NFJMKROFSA-N (2s)-2,3-diaminobutanoic acid Chemical compound CC(N)[C@H](N)C(O)=O SXGMVGOVILIERA-NFJMKROFSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
- OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical compound NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 abstract 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente se describen análogos del GRF nóveles con actividad de GRF como así también los usos de los mismos, por ejemplo como receptores agonistas del GRF, p. ej., para inducir la secreción de la hormona de crecimiento en un sujeto o sistema biológico. Reivindicación 1: Un análogo del factor liberador de la hormona de crecimiento (GRF) que comprende un dominio de la fórmula (1) (SEQ ID Nº 1): X¹-X²-Asp-Ala-Ile-Phe-Thr-X⁸-X⁹-Tyr-X¹¹-X¹²-X¹³-Leu-X¹⁵-GIn-Leu-X¹⁸-X¹⁹-Arg-GIn-X²²-X²³-X²⁴-X²⁵-X²⁶-X²⁷-X²⁸-X²⁹-X³⁰-X³¹-X³²-X³³ (1) donde: X¹ es Tyr o His; X² es Ala, D-Ala, Ser, Leu, ácido a-aminoisobutirico (Aib), Val o Gly; X⁸ es Asn, Asp, Ala, Gln, Ser o Aib; X⁹ es Ser, Asp o Ala; X¹¹ es Arg o L-Homoarginina (HoArg); X¹² es Lys, L-Ornitina (Orn) o HoArg; X¹³ es Val o Ile; X¹⁵ es Gly o Ala; X¹⁸ es Lys, L-Ornitina, L-2,4-ácido diaminobutírico, L-2,3-ácido diaminobutírico, o Ser; X¹⁹ es Ala o Leu; X²² es Asp o Glu; X²³ es Ile o Leu; X²⁴ es Met, Ile, Nle o Leu; X²⁵ es Ser, Asn, Aib o Ala; X²⁶ es Arg, D-Arg, HoArg o Lys; X²⁷ es Ala o está ausente; X²⁸ es Ala o está ausente; X²⁹ es Arg o está ausente; X³⁰ es Ala o está ausente; X³¹ es Ala o está ausente; X³² es Arg o está ausente; X³³ es L-Homoserina (HoSer) o está ausente; y donde si X¹⁸ es Ser, X²⁷ a X³² o X²⁷ a X³³ están presentes, o una sal de los mismos farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477775P | 2011-04-21 | 2011-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087727A1 true AR087727A1 (es) | 2014-04-16 |
Family
ID=47021786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101345A AR087727A1 (es) | 2011-04-21 | 2012-04-19 | Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8361964B2 (es) |
| EP (1) | EP2699591A4 (es) |
| JP (1) | JP6113144B2 (es) |
| KR (1) | KR20140027284A (es) |
| CN (1) | CN103547591A (es) |
| AR (1) | AR087727A1 (es) |
| BR (1) | BR112013027150A2 (es) |
| CA (1) | CA2833434A1 (es) |
| MX (1) | MX2013012259A (es) |
| WO (1) | WO2012142706A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
| CA3021231A1 (en) | 2016-04-19 | 2017-10-26 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
| JP2023533498A (ja) * | 2020-07-05 | 2023-08-03 | ゼラテクノロジーズ インコーポレイテッド | Ｇｈｒｈアナログの低用量医薬組成物及びその使用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518586A (en) | 1983-01-13 | 1985-05-21 | The Salk Institute For Biological Studies | GRF Analogs III |
| US4617149A (en) | 1983-09-21 | 1986-10-14 | Eli Lilly And Company | Growth hormone release factor analogs |
| US4622312A (en) | 1984-09-24 | 1986-11-11 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
| US4734399A (en) * | 1985-08-06 | 1988-03-29 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
| US4801456A (en) | 1987-07-09 | 1989-01-31 | International Minerals & Chemical Corp. | Growth hormone-releasing factor analogs |
| ATE106895T1 (de) * | 1987-09-18 | 1994-06-15 | Hoffmann La Roche | Zyklische grf-analoga. |
| NZ237857A (en) * | 1990-04-24 | 1992-05-26 | Lilly Co Eli | Polypeptide compounds with growth hormone releasing factor activity |
| WO1992018531A1 (en) | 1991-04-09 | 1992-10-29 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
| US5262519A (en) | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
| AU5441096A (en) | 1995-04-14 | 1996-10-30 | The Administrators Of The Tulane Eductional Fund | Analogs of growth hormone-releasing factor |
| BRPI9608799B8 (pt) | 1995-05-26 | 2019-11-05 | Theratechnologies Inc | análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica. |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| US6057422A (en) | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
| WO2002028437A1 (en) | 2000-10-05 | 2002-04-11 | Ares Trading S.A. | Regioselective liquid phase pegylation |
| EP1355941A2 (en) * | 2001-02-02 | 2003-10-29 | ConjuChem, Inc. | Long lasting growth hormone releasing factor derivatives |
| JP3996897B2 (ja) * | 2001-06-08 | 2007-10-24 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | ソマトスタチン−ドーパミンキメラ類似体 |
| CA2496687A1 (en) | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
| EP1628676A1 (en) | 2003-05-29 | 2006-03-01 | Theratechnologies Inc. | Grf analog compositions and their use |
| TW200517400A (en) | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
| JP4726797B2 (ja) | 2003-10-20 | 2011-07-20 | セラテクノロジーズ・インコーポレーテッド | 消耗症に罹患している患者の治療における成長ホルモン放出因子類似体の使用 |
| KR101228229B1 (ko) | 2004-10-20 | 2013-01-31 | 쎄러테크놀로지스 인코포레이티드 | 성장 호르몬 분비 촉진물질 및 그의 용도 |
| US8021859B2 (en) | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US20090088380A1 (en) | 2007-07-12 | 2009-04-02 | Pierrette Gaudreau | Ghrh analogs and therapeutic uses thereof |
| US20110021429A1 (en) | 2007-10-01 | 2011-01-27 | Pierrette Gaudreau | Renoprotection by growth hormone-releasing hormone and agonists |
| US20100267636A1 (en) | 2009-04-20 | 2010-10-21 | Theratechnologies Inc. | Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy |
-
2012
- 2012-04-17 MX MX2013012259A patent/MX2013012259A/es active IP Right Grant
- 2012-04-17 CN CN201280024235.3A patent/CN103547591A/zh active Pending
- 2012-04-17 JP JP2014505470A patent/JP6113144B2/ja not_active Expired - Fee Related
- 2012-04-17 CA CA2833434A patent/CA2833434A1/en not_active Abandoned
- 2012-04-17 KR KR1020137030657A patent/KR20140027284A/ko not_active Application Discontinuation
- 2012-04-17 EP EP12774217.9A patent/EP2699591A4/en not_active Withdrawn
- 2012-04-17 BR BR112013027150A patent/BR112013027150A2/pt not_active IP Right Cessation
- 2012-04-17 US US13/448,660 patent/US8361964B2/en not_active Expired - Fee Related
- 2012-04-17 WO PCT/CA2012/050242 patent/WO2012142706A1/en active Application Filing
- 2012-04-19 AR ARP120101345A patent/AR087727A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013012259A (es) | 2013-11-22 |
| CA2833434A1 (en) | 2012-10-26 |
| WO2012142706A1 (en) | 2012-10-26 |
| JP6113144B2 (ja) | 2017-04-12 |
| US8361964B2 (en) | 2013-01-29 |
| US20120270784A1 (en) | 2012-10-25 |
| JP2014515751A (ja) | 2014-07-03 |
| CN103547591A (zh) | 2014-01-29 |
| EP2699591A1 (en) | 2014-02-26 |
| KR20140027284A (ko) | 2014-03-06 |
| EP2699591A4 (en) | 2014-05-07 |
| BR112013027150A2 (pt) | 2017-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2952095C (en) | Use of melanocortins to treat insulin sensitivity | |
| AR105816A2 (es) | Derivados de exendina-4 funcionalizada | |
| GT201200263A (es) | "nuevos peptidos y metodos para su preparacion y uso" | |
| AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
| NI201200134A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
| JP2015528795A5 (es) | ||
| NZ613809A (en) | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| AR078950A1 (es) | Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales | |
| ES2531083T3 (es) | Formulaciones estables de polipéptidos y usos de las mismas | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| CO6541617A2 (es) | Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| AR087727A1 (es) | Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos | |
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| US20120135923A1 (en) | Use of Melanocortins to Treat Dyslipidemia | |
| Jankowski et al. | Oxytocin in the heart regeneration | |
| ES2723098T3 (es) | Agonistas del péptido CRHR2 y usos de los mismos | |
| AR098732A1 (es) | Un proceso para la preparación de una composición de proteínas pegiladas | |
| Naono-Nakayama et al. | Pharmacological characteristics of endokinin C/D-derived peptides in nociceptive and inflammatory processing in rats | |
| AR117619A1 (es) | Compuestos coagonistas de gip / glp1 | |
| AR118601A2 (es) | Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral | |
| Prunier et al. | Response of blood hormones and nutrients to stress in male pigs differing by their gonadal status | |
| Shikano et al. | 3‐[123I] IODO‐α‐methyl‐L‐tyrosine as a substrate of human L‐type amino acid transporter‐1 | |
| Burns et al. | Bombesin antagonists have agonist activity in breast cancer lines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |